Cocaine Use Disorders Clinical Trial
The research proposed in this application will determine the initial efficacy, safety and tolerability of a novel drug combination, bupropion and naltrexone, as a pharmacotherapy for cocaine dependence. A rigorous, inpatient human laboratory study will be conducted. The proposed study is innovative and important because it will provide the impetus for the conduct of double blind, placebo-controlled trials to further demonstrate the efficacy of bupropion-naltrexone combinations for managing cocaine dependence.
Cocaine (COC) dependence is a significant public health concern. A widely effective
pharmacotherapy has not yet been identified for COC dependence. Innovative strategies are
needed to identify an effective pharmacotherapy for COC dependence. Testing medications
effective for disorders that share neurobiological substrates with drug dependence, for
example, could yield treatments for managing COC dependence.
Obesity is also a significant public health concern. Although obesity and COC dependence are
typically considered distinct clinical entities, both diseases involve perturbations of
central biogenic amine and/or hypothalamic-melanocortin systems. The obesity epidemic has
spurred development of medications to promote weight loss. A combination of bupropion (BUP)
and naltrexone (NTX) is effective for obesity. The overarching goal of this application is to
demonstrate the initial efficacy, safety, and tolerability of BUP-NTX combinations for COC
dependence. A mixed-model experiment will be conducted in which separate cohorts of
non-treatment-seeking, COC-dependent participants will be randomized to different maintenance
doses of NTX (i.e., NTX is a between-subject factor). Participants (N=12) in each NTX cohort
will be maintained concurrently on BUP (i.e., BUP is a within-subject factor). The
reinforcing effects of intranasal COC will be determined after participants in each NTX
cohort are maintained for 4-7 days on each of the BUP doses (i.e., COC is a within-subject
factor). COC (0, 40 and 80 mg) will be tested with multiple dose combinations of BUP (0, 100,
200, 400 mg/day) and NTX (0, 25, 50 mg/day). The proposed study will also identify the
optimal dose combination of BUP and NTX that most effectively attenuates the reinforcing
effects of COC.
This research will provide critical information regarding the initial efficacy and optimal
doses of a novel drug combination, BUP and NTX, for COC dependence, which will enhance the
probability of success when advanced to a clinical trial. Innovations of the proposed
research include: 1) testing a combination of marketed drugs that demonstrated modest
efficacy when tested as mono-therapies; 2) the use of a sophisticated drug
self-administration procedure; 3) providing the impetus for the conduct of a Phase II
clinical trial to further demonstrate the efficacy of BUP-NTX combinations for COC
dependence; and 4) demonstrating the initial efficacy and optimal doses of a combination of
commercially available drugs, as opposed to waiting for novel molecules to be available for
testing in humans, thereby impacting clinical research and practice more quickly. In these
ways, the proposed project will shift the current clinical research paradigm in
pharmacotherapy development and have a significant impact on the treatment of COC dependence.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01639157 -
Impact of Buspirone Maintenance on the Reinforcing Effects of Cocaine
|
N/A | |
Completed |
NCT00759473 -
D-Cycloserine Facilitation of Cocaine - Cue Extinction
|
Phase 2 | |
Completed |
NCT00780442 -
D-Cycloserine and Cue Exposure in Cocaine-Dependent Individuals
|
Phase 2 | |
Completed |
NCT00178776 -
A Transtheoretical Model Group Therapy for Cocaine
|
Phase 1 | |
Recruiting |
NCT02680288 -
Lorcaserin Intra Venous Cocaine Effects
|
Phase 1/Phase 2 | |
Completed |
NCT02909101 -
Project IMPACT: Improving Memory Performance by Applying Cognitive Training
|
N/A | |
Completed |
NCT01495195 -
Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior
|
Phase 2 | |
Completed |
NCT02373124 -
Glutamatergic Modulation of Motivation Enhancement: A Pilot Feasibility Trial
|
Phase 1/Phase 2 |